Drug intelligence / Profile preview

ALN-TMP

Development stage: Phase 1
Lead developer: Alnylam Pharmaceuticals
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

ALN-TMP (also known as AG-236) is an RNAi therapeutic developed by Alnylam Pharmaceuticals and Agios Pharmaceuticals. It is designed to treat polycythemia vera by targeting and silencing the expression of the TMPRSS6 gene through RNA interference.

Targets

TMPRSS6 (Transmembrane Serine Protease 6)

Beyond the preview

Go deeper on ALN-TMP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALN-TMP.

Explore the full profile